Direct aortic approach feasible for Medtronic's CoreValve heart implant
New data from a study of Medtronic's CoreValve transcatheter aortic valve implant shows that the direct aortic implantation approach is feasible.
Medtronic (NYSE:MDT) presented new data from a clinical trial of its CoreValve heart implant at the PCR London Valves 2012 meeting, showing that the direct aortic approach is feasible, and launched another trial of the transcatheter aortic valve implant.
The Fridley, Minn.-based medical device company said the 151-patient study showed 97% procedural success with no procedural deaths, a 30-day mortality rate of 8.6% and a 3.9% incidence of stroke.
Medtronic also said it's launched the CoreValve Advance direct aortic study to examine the safety and effectiveness of the procedure.